Altium International is pleased to announce a new partnership with DPBio, a pioneering innovator in high-throughput droplet microfluidic technology. Through this collaboration, Altium expands its portfolio of advanced cell analysis solutions with next-generation systems designed to transform antibody discovery, enzyme evolution, and single-cell functional screening.
DPBio integrates precision engineering and biological insight to deliver fully automated, scalable tools for microfluidic research. Their technologies enable scientists to encapsulate and analyze millions of single cells within picoliter droplets, each acting as a miniature bioreactor, providing unparalleled throughput and resolution for discovering and characterizing functional antibodies.
At the heart of DPBio’s portfolio are two complementary systems:
- CytoSpark® CSP – a microfluidic high-throughput screening platform capable of detecting and sorting millions of single B-cells within 1–2 days, accelerating workflows in antibody development.
OMNIdrop – an all-in-one droplet microfluidic analysis system integrating generation, detection, and sorting in a single platform, ideal for developing and optimizing microdroplet-based methodologies in antibody discovery, cell engineering, and omics research.
With this partnership, Altium International continues to strengthen its commitment to providing scientists with the most advanced tools for functional cell analysis and biotherapeutic innovation. By combining DPBio’s cutting-edge microfluidic systems with Altium’s regional expertise and support, researchers can now access streamlined solutions that bridge single-cell biology and next-generation drug discovery.
